MedTrace Logo

The Role of Immune Semaphorins in Steatotic Liver Disease and Sepsis

NCT06021743 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2023-09-07

No results posted yet for this study

Summary

The impact of the complex liver immunological network on sepsis outcome is largely unknown. Steatotic liver disease (SLD) is the most common chronic liver disease with prevalence of 25% in European countries. The question remains whether patients with SLD are more prone to bacterial infections and what is the impact of persistent liver inflammation to the systemic response to infection, sepsis course and outcomes. Semaphorins are a large family of secreted and membrane-bound biological response modifiers present in many organ systems that are associated with SLD and development of fibrosis, but also might regulate systemic immune responses in sepsis. This study will investigate the association of semaphorins with sepsis outcomes in patients with SLD.

Conditions

  • Steatosis of Liver
  • Sepsis
  • Immune Response

Interventions

DIAGNOSTIC_TEST

Evaluation of the degree of steatosis

The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.

DIAGNOSTIC_TEST

Screening for the components of metabolic syndrome

Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.

DIAGNOSTIC_TEST

Measurement of serum semaphorin concentrations

Semaphorin concentration will be measured in patient sera by ELISA.

DIAGNOSTIC_TEST

Measurement of inflammatory cytokines

A panel of pro- and anti-inflammatory markers will be determined by flow cytometer microsphere-based assay.

Sponsors & Collaborators

  • Croatian Science Foundation

    collaborator OTHER_GOV

  • University Hospital for Infectious Diseases, Croatia

    lead OTHER

Principal Investigators

  • Neven Papic, MD, PhD · School of Medicine, University of Zagreb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-02-28
Completion
2024-03-01

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06021743 on ClinicalTrials.gov